A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to establish a recommended dose of Alpharadin to be used in
combination with docetaxel in patients with bone metastases from castration-resistant
prostate cancer and to investigate safety and explore efficacy of the recommended dose.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Bayer
Treatments:
Dexamethasone Docetaxel Prednisone Radium Ra 223 dichloride Succinylcholine